A beta-adrenoceptor blocking agent, befunolol as a partial agonist in isolated organs

Area of Science:

• Pharmacology
• Adrenoceptor Research
• Ophthalmology Drug Action

Background:

• Befunolol is a beta-adrenoceptor antagonist used for glaucoma treatment in Japan.
• Understanding the full pharmacological profile of existing drugs is crucial for optimizing therapeutic use.

Purpose of the Study:

• To investigate the intrinsic sympathomimetic activities of befunolol.
• To explore the mechanism underlying befunolol's interaction with beta-adrenoceptors.

Main Methods:

• Assessment of befunolol's intrinsic activities in isolated guinea pig organs (atria, trachea, taenia caecum).
• Comparison of befunolol's pD2 values (agonist potency) with its pA2 values (antagonist potency) against isoprenaline.

Main Results:

• Befunolol demonstrated intrinsic sympathomimetic activities (0.22-0.28) in isolated guinea pig tissues.
• Significant differences were observed between befunolol's pD2 and pA2 values, indicating complex receptor interactions.

Conclusions:

• Befunolol's activity profile suggests interaction with two distinct sites on the beta-adrenoceptor: one for agonistic and one for antagonistic action.
• These sites are likely mutually exclusive, and befunolol's intrinsic activity may reflect its selectivity for these sites.